title: Prevalence, awareness, treatment, and control of hypertension among Canadian adults with diabetes, 2007 to 2009.
abstract: BACKGROUND
  Prior national surveys suggested that treatment and control of hypertension were poor in individuals with diabetes. Using measured blood pressures, we estimated prevalence, awareness, treatment, and control of hypertension between 2007 and 2009 among Canadians with diabetes and sought to determine whether a treatment gap still exists for individuals with diabetes.
  
  
  METHODS
  Using data from cycle 1 of the Canadian Health Measures Survey, estimates of hypertension prevalence, awareness, treatment, and control were described and compared between individuals with and without self-reported diabetes.
  
  
  RESULTS
  Three-quarters of individuals reporting diabetes also had hypertension; of these, 89% (95% confidence interval [CI], 80%-98%) were aware, 88% (95% CI, 81%-94%) were treated, and 56% (95% CI, 45%-66%) were controlled to < 130/80 mm Hg. Among those treated with pharmacotherapy, 39% (95% CI, 31%-48%) were using monotherapy, 29% (95% CI, 18%-40%) were taking 2 medications, and 31% (95% CI, 22%-39%) were taking 3 or more medications; control to < 130/80 mm Hg was achieved by 63% (95% CI, 53%-74%). Among those treated, individuals with diabetes were significantly less likely to be treated to their recommended target (< 130/80 mm Hg) compared with individuals without diabetes (< 140/90 mm Hg; odds ratio(adjusted) 0.3; 95% CI, 0.2-0.6).
  
  
  CONCLUSIONS
  Hypertension treatment and control among people with diabetes have improved in Canada during the past 2 decades. Nonetheless, nearly half of people with diabetes are above the treatment target. Health care professionals should continue to increase their efforts in supporting patients with diabetes in achieving blood pressure control, with emphasis on lifestyle management and pharmacotherapy.
authors.affiliation: Department of Community Health and Epidemiology, Queen's University, Kingston, Ontario, Canada.
authors.forename: Marianne E
authors.initials: ME
authors.lastname: Gee
authors.forename: Ian
authors.initials: I
authors.lastname: Janssen
authors.forename: William
authors.initials: W
authors.lastname: Pickett
authors.forename: Finlay A
authors.initials: FA
authors.lastname: McAlister
authors.forename: Christina M
authors.initials: CM
authors.lastname: Bancej
authors.forename: Michel
authors.initials: M
authors.lastname: Joffres
authors.forename: Helen
authors.initials: H
authors.lastname: Johansen
authors.forename: Norman R C
authors.initials: NR
authors.lastname: Campbell
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001364:Awareness; D002170:Canada / Q000453:epidemiology; D015897:Comorbidity; D016001:Confidence Intervals; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006306:Health Surveys; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents